title: Factors influencing treatment results in pseudophakic endophthalmitis.
abstract: OBJECTIVE
  To evaluate risk factors, therapeutic approaches and factors associated with the poor visual outcome in pseudophakic endophthalmitis.
  
  
  METHODS
  Data related to 28 cases with the diagnosis of endophthalmitis after cataract surgery and IOL implantation were gathered retrospectively.
  
  
  RESULTS
  Preceding surgery was extracapsular cataract extraction (ECCE) in 18, phacoemulsification in 8 and scleral fixated intraocular lens implantation in two cases. Posterior capsule rupture and diabetes mellitus were considered to contribute to the development of endophthalmitis because of their high incidences (50% and 25%) in the study group. Microbiological studies from aqueous and vitreous humour were done in 85% of the cases and 58% were positive. S. Epidermidis was the most common organism, accounting for 50% of the isolates. All cases were given topical and systemic antibiotics. Inflammation was controlled by addition of subconjunctival antibiotics to this regimen in two, intravitreal antibiotic injection in 14, pars plana vitrectomy, total capsular and lens extraction and intravitreal antibiotic injection in three, lens exchange, intracapsular and intravitreal antibiotic injection in three cases. Six (21%) cases eventually needed evisceration. Visual acuity of 20/40 or better was achieved in 25%, and 20/100 or better in 64%.
  
  
  CONCLUSIONS
  Treatment delay (p=0.039), capsular rupture complicating cataract surgery, especially with extracapsular cataract extraction (p=0.015), and initial visual acuity worse than hand motion (p=0.003) were strong predictors of poor visual outcome. The risk of endophthalmitis was not different forplanned ECCCE (0.26%) andphacoemulsification (0.27%) but the prognosis was better with the latter.
authors.affiliation: SSK Ankara Eye Disease Hospital, Turkey. dr_feray@yahoo.com
authors.forename: F
authors.initials: F
authors.lastname: Koç
authors.forename: E
authors.initials: E
authors.lastname: Sen
authors.forename: P
authors.initials: P
authors.lastname: Demirbay
authors.forename: I
authors.initials: I
authors.lastname: Taşkintuna
authors.forename: M Y
authors.initials: MY
authors.lastname: Teke
authors.forename: P
authors.initials: P
authors.lastname: Ozdal
authors.forename: S
authors.initials: S
authors.lastname: Ortaç
authors.forename: O
authors.initials: O
authors.lastname: Oz
authors.forename: F
authors.initials: F
authors.lastname: Tarkan
authors.forename: E
authors.initials: E
authors.lastname: Firat
mesh_terms: D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001082:Aqueous Humor / Q000382:microbiology; D001419:Bacteria / Q000302:isolation & purification; D009877:Endophthalmitis / Q000382:microbiology / Q000628:therapy*; D017234:Eye Evisceration; D015818:Eye Infections, Bacterial / Q000382:microbiology / Q000628:therapy*; D005260:Female; D006801:Humans; D019654:Lens Implantation, Intraocular; D008297:Male; D008875:Middle Aged; D018918:Phacoemulsification; D019591:Pseudophakia / Q000382:microbiology / Q000628:therapy*; D012189:Retrospective Studies; D012307:Risk Factors; D016896:Treatment Outcome; D014792:Visual Acuity; D014821:Vitrectomy; D014822:Vitreous Body / Q000382:microbiology
chemical_list: D000900:Anti-Bacterial Agents